Micah Lee Romero, MA, PLPC | |
3600 Jackson St Ste 119, Alexandria, LA 71303-3096 | |
(318) 625-7050 | |
(318) 625-7197 |
Full Name | Micah Lee Romero |
---|---|
Gender | Male |
Speciality | Case Manager/care Coordinator |
Location | 3600 Jackson St Ste 119, Alexandria, Louisiana |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1346017662 | NPI | - | NPPES |
3506 | Other | LA | OTHER |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101Y00000X | Counselor | PLC9183 (Louisiana) | Secondary |
171M00000X | Case Manager/care Coordinator | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Micah Lee Romero, MA, PLPC 1330 W Mcneese St Apt 4206, Lake Charles, LA 70605-4493 Ph: (337) 499-1079 | Micah Lee Romero, MA, PLPC 3600 Jackson St Ste 119, Alexandria, LA 71303-3096 Ph: (318) 625-7050 |
News Archive
Researchers have identified a subset of B cells that contribute to multiple sclerosis pathology independently of antibody production.
A new study conducted by the Center for Injury Research and Policy and the Central Ohio Poison Center at Nationwide Children's Hospital found that there were more than 156,000 calls to US Poison Control Centers regarding exposures to attention-deficit hyperactivity disorder medications among children and adolescents 19 years of age and younger from January 2000 through December 2014, averaging 200 calls each week or 29 calls per day.
Cosmetic surgery is everywhere these days: TV, magazines, the Internet and more. And according to new data, society is indeed more comfortable talking about cosmetic surgery than ever before.
CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announced today that the China Food and Drug Administration (CFDA) has approved the Company's application to conduct a Phase 2 global clinical trial in ovarian clear cell carcinoma (OCCC) patients for its proprietary drug candidate ENMD-2076.
› Verified 5 days ago